Compare KEX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEX | KYMR |
|---|---|---|
| Founded | 1921 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.8B |
| IPO Year | 1994 | 2020 |
| Metric | KEX | KYMR |
|---|---|---|
| Price | $136.52 | $74.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 26 |
| Target Price | ★ $127.75 | $107.72 |
| AVG Volume (30 Days) | ★ 652.3K | 622.7K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.92 | N/A |
| EPS | ★ 6.33 | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $4.19 | $16.05 |
| Revenue Next Year | $7.56 | $4.79 |
| P/E Ratio | $20.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.52 | $19.45 |
| 52 Week High | $134.69 | $103.00 |
| Indicator | KEX | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 35.15 |
| Support Level | $109.37 | $64.95 |
| Resistance Level | N/A | $77.93 |
| Average True Range (ATR) | 4.55 | 3.66 |
| MACD | 0.52 | -1.19 |
| Stochastic Oscillator | 92.46 | 5.84 |
Kirby Corp is a domestic tank barge operator, transporting bulk liquid products throughout three United States coasts. The Company transports petrochemicals, liquid cargoes, inland waterway systems, and dry bulk cargoes. The Company conducts operations in two reportable business segments: The Marine transportation segment which provides marine transportation services, operating tank barges and towing vessels transporting bulk liquid products, and the Distribution and services segment, which provides after-market service, and genuine replacement parts for engines, transmissions, reduction gears, and power generation equipment used in oil and gas and commercial and industrial applications. The company's revenue is generated from the Marine Transportation segment.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.